Methods	Six-week double-blind, randomised study.
Participants	Outpatients satisfying the DSM criteria for bipolar disorder, fulfilling DSM-III criteria for major depressive disorder, with a score of at least 20 on the HDRS-21 and at least 8 on the Raskin Scale. Age range: 18-70 years. Exclusion criteria: serious physocal illness, chronic or acute organic brain symptoms, epilepsy, alcoholism, drug addiction
Interventions	Fluoxetine: 30 participants. Imipramine: 30 participants. Placebo: 29 participants. Fluoxetine dose range: 20-80 Imipramine dose range: 75-300. The only allowed concomitant psychotropic drugs were lithium and chloral hydrate (max 1 g)
Outcomes	Hamilton Rating Scale for Depression, Raskin Depression Scale, Covi Anxiety Scale, CGI-Severity, CGI-Global Improvement, PGI
Notes	Response: decrease of at least 50% in the HAM-D. Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear